bedaquiline

Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

(1S,2R)-Bedaquiline ((1S,2R)-TMC207) is a pharmaceutical intermediate utilized in the synthesis of various active compounds.

(Rac)-Bedaquiline is the racemic form of Bedaquiline. Bedaquiline (TMC207) acts as a diarylquinoline agent that targets the c- and ε-subunits to inhibit Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase. It possesses uncoupler activity and is employed in the treatment of multidrug-resistant tuberculosis.

Bedaquiline fumarate (TMC207), a diarylquinoline antibiotic that targets ATP synthase, is effective for the treatment of Mycobacterium tuberculosis infections. It blocks the proton pump for ATP synthase of mycobacteria. It is the first member of a new class of drugs called diarylquinolines.

(Rac)-Bedaquiline-d6 is a deuterium-labeled version of Bedaquiline. Bedaquiline (TMC207) is a diarylquinoline compound that targets the c and ε subunits to inhibit Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase. Levomefolic acid exhibits uncoupling activity and is used in the treatment of multidrug-resistant tuberculosis.

Bedaquiline impurity 2-d6 is a deuterated form of Bedaquiline. Bedaquiline (TMC207) is a diarlyquinoline active compound that inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase by targeting both the c-subunit and ε-subunit simultaneously. It exhibits uncoupling activity and has potential use for multidrug-resistant tuberculosis.

Bedaquiline (Standard) is a reference standard for research and analysis in studies involving Bedaquiline. Bedaquiline (R207910) is an anti-tuberculosis drug which selectively inhibit the mycobacterial energy metabolism i.e. ATP synthesis and found to be effective against all states of Mycobacterium tuberculosis.

UH-NIP-16 exhibits antibacterial activity against Mycobacterium tuberculosis, effectively inhibiting the pathogenic mycobacterium strains H37Rv and CDC1551 with MIC50 values of 1.86 and 3.05 μM, respectively. Additionally, UH-NIP-16 synergistically enhances the antitubercular effects when used with antituberculosis agents such as Streptomycin, Isoniazid, Ethambutol, and Bedaquiline.

(Rac)-TBAJ-876, a racemate of its counterpart TBAJ-876, acts as an inhibitor of Mycobacterium tuberculosis. It is an analogue of the anti-tuberculosis agent Bedaquiline, indicating its potential in tuberculosis research.